Combination therapy: Abiraterone prolongs survival in metastatic prostate cancer

Nature Reviews Clinical Oncology

Volumn 8, Issue 9, 2011, Pages 515-516

  Sartor, Oliver ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [3 [4 CYANO 3 (TRIFLUOROMETHYL)PHENYL] 5,5 DIMETHYL 4 OXO 2 THIOXO 1 IMIDAZOLIDINYL] 2 FLUORO N METHYLBENZAMIDE; ABIRATERONE; CABAZITAXEL; DOCETAXEL; ESTRAMUSTINE; ESTROGEN; MITOXANTRONE; PLACEBO; PREDNISONE; PROVENGE; TESTOSTERONE;

ARTICLE; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; HUMAN; METASTASIS POTENTIAL; MONOTHERAPY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; TESTOSTERONE BLOOD LEVEL;

ANDROGEN ANTAGONISTS; ANDROSTENOLS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; MALE; PROSTATIC NEOPLASMS; STEROID 17-ALPHA-HYDROXYLASE;

EID: 80052204537     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2011.111     Document Type: Article

References (9)

1. de Bono, J. S. et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364, 1995-2005 (2011).
2. Huggins, C. & Hodges, C. V. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection, on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1, 293-297 (1941).
3. The Leuprolide Study Group. Leuprolide versus diethylstilbestrol for metastatic prostate cancer. N. Engl. J. Med. 311, 1281-1286 (1984).
4. Petrylak, D. P. et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 351, 1513-1520 (2004). (Pubitemid 39315318)
5. Tannock, I. F. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351, 1502-1512 (2004). (Pubitemid 39315317)
6. Kantoff, P. W. et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 411-422 (2010).
7. de Bono, J. S. et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet 376, 1147-1154 (2010). 8. Bayer Press Server. Alpharadin significantly improves overall survival in phase III Trial in patients with castration-resistant prostate cancer that has spread to the bone [online], http://www.press.bayer.com/baynews/baynews.nsf/id/Alpharadin- Significantly-Improves-Overall-Survival-Phase-III-Trial-Patients-Castration- Resistant (2011).
8. Logothetis, C. et al. Effect of abiraterone acetate (AA) on pain control and skeletal-related events (SRE) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) post docetaxel (D): Results from the COU-AA-301 phase III study. [abstract 4520]. J. Clin. Oncol. 29 (2011).
9. Scher, H. I. et al. Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): Planned final analysis (FA) of COU-AA-301, a randomized double-blind, placebo-controlled phase III study of abiraterone acetate (AA) plus low-dose prednisone (P) post docetaxel. [abstract LBA4517]. J. Clin. Oncol. 29 (2011).